ArticlePloS one2021

Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.

Ben Parker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.